Profund Advisors LLC reduced its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 44.8% in the first quarter, according to its most recent filing with the SEC. The fund owned 28,858 shares of the pharmaceutical company’s stock after selling 23,406 shares during the quarter. Profund Advisors LLC’s holdings in GlaxoSmithKline were worth $1,127,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of GSK. Toronto Dominion Bank boosted its position in shares of GlaxoSmithKline by 133.3% during the 1st quarter. Toronto Dominion Bank now owns 3,150 shares of the pharmaceutical company’s stock valued at $123,000 after acquiring an additional 1,800 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new stake in GlaxoSmithKline during the 1st quarter valued at $135,000. Amussen Hunsaker Associates LLC purchased a new stake in GlaxoSmithKline during the 4th quarter valued at $141,000. First Dallas Securities Inc. purchased a new stake in GlaxoSmithKline during the 4th quarter valued at $142,000. Finally, Centaurus Financial Inc. purchased a new stake in GlaxoSmithKline during the 1st quarter valued at $157,000. Hedge funds and other institutional investors own 11.09% of the company’s stock.
NYSE:GSK opened at $41.19 on Tuesday. The company has a debt-to-equity ratio of 3.90, a quick ratio of 0.40 and a current ratio of 0.61. GlaxoSmithKline plc has a fifty-two week low of $34.52 and a fifty-two week high of $44.44. The firm has a market cap of $101.71 billion, a P/E ratio of 14.30, a P/E/G ratio of 2.19 and a beta of 0.83.
GlaxoSmithKline (NYSE:GSK) last released its earnings results on Wednesday, April 25th. The pharmaceutical company reported $0.68 earnings per share for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.02). GlaxoSmithKline had a return on equity of 144.84% and a net margin of 3.50%. The business had revenue of $10.04 billion during the quarter, compared to analysts’ expectations of $10.26 billion. sell-side analysts forecast that GlaxoSmithKline plc will post 2.84 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 12th. Shareholders of record on Friday, May 11th will be paid a $0.5298 dividend. The ex-dividend date is Thursday, May 10th. This represents a $2.12 dividend on an annualized basis and a yield of 5.14%. GlaxoSmithKline’s payout ratio is 72.92%.
Several analysts recently weighed in on GSK shares. Zacks Investment Research lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Wednesday, March 21st. Deutsche Bank restated a “neutral” rating on shares of GlaxoSmithKline in a report on Wednesday, March 28th. Finally, BNP Paribas upgraded GlaxoSmithKline from a “neutral” rating to an “outperform” rating in a report on Wednesday, April 4th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company’s stock. GlaxoSmithKline has a consensus rating of “Hold” and an average price target of $40.21.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.